Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated ...

Thorn and Eder 5 again reviewed the literature in 1946 and stated: "The combination of myasthenia gravis and Graves' disease is rare. To date, six cases have been reported." They added 2 cases.

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Most people who get myasthenia gravis have no family history of the disease. But at least 5% of folks with MG may have another family member with MG or another autoimmune condition. Your ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Myasthenia gravis is considered to be an autoimmune disorder. In an autoimmune disease, some of the body's antibodies (special proteins in your body that are programmed to fight foreign invaders ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular ... Kettles VA Medical Center in Michigan, who has co-authored MG research. The disease disrupts communication between nerves ...

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include ... there was a 68% reduction in disease exacerbations, a 71% reduction ...

Nipocalimab led to significant improvements in disease-specific metrics from baseline among patients with myasthenia gravis. Treatment was well-tolerated, with no serious adverse events.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...